Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders |
IRONWOOD PHARMACEUTICALS INC (IRWD)
|
Add to portfolio |
|
|
Price: |
$11.95
| | Metrics |
OS: |
156.0
|
M
| |
|
|
Market cap: |
$1.86
|
B
| |
|
|
Net debt:
|
$622
|
M
| |
2.7
|
x Debt/EBITDA
|
EV:
|
$2.49
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
$232
|
M
| |
10.7
|
x EV/EBITDA
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 413.8 | 389.5 | 428.4 | 346.6 | 298.3 | 274.0 | 149.6 | 76.4 |
Revenue growth | 6.2% | -9.1% | 23.6% | 16.2% | 8.9% | 83.2% | 95.7% | 234.1% |
Cost of goods sold | 0.0 | 3.1 | 23.9 | 32.8 | 19.1 | 1.9 | 0.0 | 5.3 |
Gross profit | 413.8 | 386.4 | 404.5 | 313.9 | 279.2 | 272.1 | 149.5 | 71.1 |
Gross margin | 100.0% | 99.2% | 94.4% | 90.6% | 93.6% | 99.3% | 100.0% | 93.1% |
Selling, general and administrative | 111.1 | 140.0 | 172.5 | 219.7 | 231.2 | 173.3 | 125.2 | 118.3 |
Research and development | 70.4 | 88.1 | 115.0 | 101.1 | 88.1 | 139.5 | 108.7 | 101.9 |
EBITA | 221.4 | 146.2 | 123.7 | -7.1 | -40.5 | -41.1 | -102.1 | -169.4 |
EBITA margin | 53.5% | 37.5% | 28.9% | -2.0% | -13.6% | -15.0% | -68.3% | -221.6% |
Amortization of intangibles | | | | 8.1 | 6.2 | 1.0 | | |
EBIT | 221.4 | 146.2 | 123.7 | -15.2 | -46.7 | -42.0 | -102.1 | -169.4 |
EBIT margin | 53.5% | 37.5% | 28.9% | -4.4% | -15.6% | -15.3% | -68.3% | -221.6% |
Pre-tax income | 200.7 | 108.9 | 58.9 | -194.1 | -54.9 | -81.7 | -142.7 | -189.6 |
Income taxes | -327.8 | 2.7 | 37.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | | 2.5% | 63.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Earnings from continuing ops | 528.4 | 106.2 | 96.4 | -105.9 | 7.1 | -81.7 | -142.7 | -189.6 |
Earnings from discontinued ops | | | -37.4 | -88.2 | -62.0 | | | |
Net income | 528.4 | 106.2 | 58.9 | -194.1 | -54.9 | -81.7 | -142.7 | -189.6 |
Net margin | 127.7% | 27.3% | 13.8% | -56.0% | -18.4% | -29.8% | -95.4% | -248.1% |
|
Diluted EPS | $3.21 | $0.66 | $0.62 | ($0.69) | $0.05 | ($0.56) | ($1.00) | ($1.39) |
Shares outstanding (diluted) | 164.4 | 160.7 | 156.0 | 152.6 | 149.0 | 144.9 | 142.2 | 136.8 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|